patritumab
amgen,daiichi sankyo
['breast', 'patritumab', 'rux,(-crux),(-trux),(-deruxtecan)', 'rux,(-crux),(-trux)']
 #asco23 her3txd (patritumab deruxetan) in her2 negative heavily pre-treated metastatic breast ca. 35% response rate irrespective of her3 expression. promising new agent.
Breast med oncology, chief hem/onc @NYPBrooklyn, prof clinical med @WeillCornell, ethics/spirituality in medicine; long time NY #Jets sufferer; tweets my own